



IBC Meeting Minutes
Date: January 21, 2026
Location: Conf. Room 2101/2102

Voting Members Present (9):

Michael Henderson, Ph.D. (Chair)
Glen Alberts, B.S.
Pamela Bartlett, B.S.
Scott Bechaz, ILAM, RLATg
Matthew Donahue, MBA
Angie Jason (non-voting)
Lauren Miedema, B.S., MPH
Sam Pinto, B.S. (Vice Chair)
Rachael Sheridan, Ph.D.
Jennifer Steiner, Ph.D.

Voting Members Excused (2):

Craig Bickel, M.Div.
Nicholas Burton, Ph.D.

Christy Goss (guest)

Call to Order

Michael Henderson called the meeting to order at 9:31 a.m.

Meeting Minutes – Minutes from the IBC meeting on 11/19/25 were approved unanimously.

Vote: (8 Total) 8 Approve 0 Disapprove 0 Abstain 0 Recuse

Matthew Donahue joined the meeting

New Business

- Discussion took place on the approval for handling AAV-exposed embryos in the Transgenics Core. EHS conducted a risk assessment and reviewed the process prior to the meeting. The committee requested a written exposure plan to cover the handling of AAV-exposed embryos. Approval was given based upon completion of the written exposure plan.

○ Vote: (9 Total) 9 Approve 0 Disapprove 0 Abstain 0 Recuse

- Discussion took place regarding upcoming EHS-led changes to the IBC form in Tick@Lab.

Protocol Reviews

A. Reference #25-0125 – Initial – Peter Jones, Ph.D.

“human TCL1A overexpression in HT116 and DK08 cells”

Primary Reviewer: Glen Alberts

The purpose of this protocol is to better understand and validate the role of TCL1A in human cancer cells using a lentiviral gene expression system to overexpress TCL1A in HCT116 and DKO8 cancer cells. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. General Information – The investigator was asked to clarify the use of face protection.
2. Personnel. The investigator was asked to clarify if any other staff members will perform any work.
3. rDNA- The investigator was asked to upload the maps for the specific packaging plasmids and expand description of commercially available product and of 2nd or 3rd generation.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2

Containment Level: BSL2

Location Assessment: Phase 2, Level 5, Room 5125W

Action: Modifications to secure approval.

Vote: (9 Total) 9 Approve 0 Disapprove 0 Abstain 0 Recuse

Meeting was adjourned at 10:00 am